858 related articles for article (PubMed ID: 17169640)
1. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
[TBL] [Abstract][Full Text] [Related]
2. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
4. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
5. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.
Rodríguez-Baño J; Alcalá J; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
J Antimicrob Chemother; 2009 Apr; 63(4):781-4. PubMed ID: 19223299
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
[TBL] [Abstract][Full Text] [Related]
9. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London.
Skippen I; Shemko M; Turton J; Kaufmann ME; Palmer C; Shetty N
J Hosp Infect; 2006 Oct; 64(2):115-23. PubMed ID: 16859810
[TBL] [Abstract][Full Text] [Related]
12. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Cueto Md; Gálvez J; Perea EJ; Pascual A
Clin Microbiol Infect; 2008 Feb; 14(2):180-3. PubMed ID: 18005358
[TBL] [Abstract][Full Text] [Related]
13. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors.
Ozgunes I; Erben N; Kiremitci A; Kartal ED; Durmaz G; Colak H; Usluer G; Colak E
Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246
[TBL] [Abstract][Full Text] [Related]
15. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
[TBL] [Abstract][Full Text] [Related]
16. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
[TBL] [Abstract][Full Text] [Related]
17. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
[TBL] [Abstract][Full Text] [Related]
19. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology.
Rodríguez-Baño J; López-Cerero L; Navarro MD; Díaz de Alba P; Pascual A
J Antimicrob Chemother; 2008 Nov; 62(5):1142-9. PubMed ID: 18641033
[TBL] [Abstract][Full Text] [Related]
20. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
